Phase II Study of JR-141 in Patients With Mucopolysaccharidosis II
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Idursulfase (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions
- Sponsors JCR Pharmaceuticals
- 19 Nov 2019 Status changed from active, no longer recruiting to completed.
- 28 Feb 2019 According to a JCR Pharmaceuticals media release, the company announced the completion of the patient enrollment for this study. The early results of this study will be announced once they are available.
- 28 Feb 2019 Planned End Date changed from 31 Mar 2019 to 30 Sep 2019.